2023
Development of Chimeric Antigen Receptor (CAR) T Cells Targeting MET in Lymphomas and Solid Tumors
Chen P, Raghunandan R, MĂĽschen M, Katz S. Development of Chimeric Antigen Receptor (CAR) T Cells Targeting MET in Lymphomas and Solid Tumors. Blood 2023, 142: 6805. DOI: 10.1182/blood-2023-186161.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaB-cell lymphomaChimeric antigen receptor T cellsAntigen receptor T cellsLarge B-cell lymphomaReceptor T cellsT cellsLymphoma cell linesHGF/METMET expressionOCI-Ly3CD69 expressionDLBCL cell linesCD19-CARSolid tumorsCell linesAnti-Met monoclonal antibodiesCD19 CAR T cellsNegative diffuse large B-cell lymphomaRefractory B-cell malignanciesLoss of CD19B-cell depletionActivation marker CD69Classic Hodgkin lymphomaJurkat T cells
2007
Pharmacologic Replacement of BIM BH3 Reactivates Apoptosis in Hematologic Cancer and Lymphoproliferative Disease.
LaBelle J, Fisher J, Katz S, Bird G, Lawrence C, Silverstein A, Walensky L. Pharmacologic Replacement of BIM BH3 Reactivates Apoptosis in Hematologic Cancer and Lymphoproliferative Disease. Blood 2007, 110: 524. DOI: 10.1182/blood.v110.11.524.524.Peer-Reviewed Original ResearchAnti-apoptotic proteinsBim-/- miceBcl-2 family protein interactionsBCL-2 domainsBH3-only proteinsRegulation of apoptosisApoptotic signaling pathwaysPro-apoptotic proteinsPromising pharmacologic strategyAnti-apoptotic targetsCellular homeostasisBH3 domainProtein interactionsDeath pathwaysProtein networkCellular survivalSignaling pathwaysApoptotic blockadesCell deathSAHBLymphoma cell linesBH3Apoptosis inductionProteinMitochondrial damage
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply